Clinical trials: Pediatric Brain Stem Glioma
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Anaplastic Astrocytoma, Brain Stem Glioma
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
This phase I/II trial studies the side effects and the best dose of veliparib when given together with radiation therapy and temozolomide and to see how well they work in treating younger patients newly diagnosed with diffuse…
- Conditions
- Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma
- Trial name
- NCT01514201
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Untreated Childhood Brain Stem Glioma
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
This phase II trial is studying how well giving motexafin gadolinium together with radiation therapy works in treating young patients with pontine glioma. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00387790
- Testing
- motexafin gadolinium, 3-dimensional conformal radiation therapy
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
This phase II trial is studying how well giving O6-benzylguanine together with temozolomide works in treating young patients with recurrent or progressive gliomas or brain stem tumors.
- Trial name
- NCT00275002
- Testing
- O6-benzylguanine, temozolomide
- Where
- 11 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Untreated Childhood Brain Stem Glioma
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079339
- Testing
- radiation therapy, tipifarnib
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma
- Trial name
- NCT02175745
- Testing
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Erik Mittra
Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain
RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously…
- Conditions
- Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity
- Trial name
- NCT00452868
- Testing
- Donepezil
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
RATIONALE: Acupressure wristbands may prevent or reduce nausea and caused by chemotherapy. It is not yet known whether standard care is more effective with or without acupressure wristbands in controlling acute and delayed…
- Conditions
- Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- SCUSF1202 (NCT01346267)
- Testing
- Real Acupressure Band
- Where
- 25 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- University of South Florida
Brain Stem Gliomas
Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
RATIONALE: Current therapies for a brain stem glioma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain stem gliomas.
- Trial name
- NCT00003459
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Diffuse Intrinsic Pontine Glioma
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible.
- Trial name
- NCT00036569
- Testing
- adjuvant therapy, pegylated interferon alfa
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma.
- Conditions
- Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma
- Trial name
- NCT00381797
- Testing
- Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness of imatinib mesylate in treating young patients…
- Trial name
- NCT00021229
- Testing
- imatinib mesylate, local irradiation therapy
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center